- Home
- Nervous System Diseases
As a leading Preclinical CRO, Alfa Cytology has dedicated significant resources to exploring the potential of poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of various nervous system diseases. PARP-1, a DNA-damage activated enzyme, has emerged as a promising therapeutic target due to its central role in the pathogenesis of several neurodegenerative disorders.
Overexpression and hyperactivation of PARP-1 have been strongly linked to the development of conditions such as stroke, Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), and Amyotrophic Lateral Sclerosis (ALS). PARP-1 hyperactivation can lead to a form of cell death known as "parthanatos," which involves NAD+ depletion, mitochondrial dysfunction, and the release of apoptosis-inducing factor (AIF). This devastating cascade of events ultimately results in widespread neuronal cell death, a hallmark of many neurodegenerative diseases.
Fig. 1 PARP-1 overactivation drives neuronal death and eventuate neuropathy following ischemic brain injury and neuronal/nerve injury respectively. (Arruri V. K., et al. 2021)
Researchers have been exploring the efficacy of PARP inhibitors in animal models of various neurological disorders. Below you will find some compelling examples from preclinical studies.
| Disease | PARP Inhibitor | Key Findings |
| Ischemic Stroke | Olaparib |
|
| Parkinson's Disease | Rucaparib |
|
| Alzheimer's Disease | Niraparib |
|
Through innovative research and advanced technology, Alfa Cytology delves into the mechanisms of PARP action and has the ability to help clients develop novel PARP inhibitors, as well as optimize the effectiveness of PARP inhibitors and identify their biomarkers, to accelerate the development of new therapies for nervous system diseases.
| ALS | Neuroinflammation | Stroke | Parkinson Disease | Neurodegenerative Diseases |
The development of effective therapies for nervous system diseases, such as ischemic stroke, Alzheimer's disease, and Parkinson's disease, relies heavily on the use of animal models. Animal models provide a controlled and replicable environment to study the underlying pathophysiology of nervous system diseases, test the safety and efficacy of new therapeutic interventions, and gain valuable insights that can guide the design of clinical trials.
Alfa Cytology is committed to advancing the field of nervous system disease research and driving the development of novel PARP inhibitor. To achieve this goal, we actively engage in collaborative efforts with leading academic institutions and pharmaceutical companies. For more information about our PARP inhibitor development program for nervous system disease or to discuss potential collaborations, please don't hesitate to contact us.
Reference
For research use only. Not intended for any clinical use.